Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.

Department of Thoracic Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77230-1402, USA.
Cancer (Impact Factor: 5.2). 01/2006; 106(2):366-74. DOI: 10.1002/cncr.21640
Source: PubMed

ABSTRACT Small cell lung carcinoma (SCLC) cell lines commonly express KIT and its ligand, stem cell factor, suggesting an autocrine loop promoting cell growth. Imatinib inhibits KIT kinase activity. SCLC cells treated with imatinib in vitro undergo cell cycle arrest. Imatinib reduces resistance to irinotecan in vitro. Common metabolic pathways suggest there may be drug interactions between imatinib and irinotecan or cisplatin. In the current study, the authors investigated the feasibility of combining these drugs in the treatment of patients with SCLC.
Two Phase I studies were conducted independently at two institutions. Patients with extensive-disease SCLC underwent therapy with cisplatin, irinotecan, and imatinib using two similar regimens. In one study, immunohistochemical analysis of the expression of potential imatinib targets was performed on pretreatment biopsy specimens, and blood specimens were collected and analyzed for imatinib, irinotecan, and cisplatin pharmacokinetic parameters.
Nine patients were enrolled and were evaluable for toxicity. A high incidence of neutropenia, diarrhea, and thrombosis was observed that precluded dose escalation. Six patients were evaluable for response after four cycles; five patients experienced a partial response and the other patient had developed progressive disease. Four of six tumor specimens tested expressed platelet-derived growth factor receptor-alpha and two expressed KIT. Irinotecan clearance was found to be significantly decreased by imatinib (P < 0.04). No significant alteration in the disposition of cisplatin was observed.
The maximum tolerated dose for this combination with granulocyte-colony-stimulating factor support was identified as imatinib at a dose of 300 mg/day with irinotecan (at a dose of 65 mg/m(2)) and cisplatin (at a dose of 30 mg/m(2)) given on Days 1 and 8, every 21 days. The decreased irinotecan clearance may explain the high incidence of diarrhea and neutropenia noted in the current study.

  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we have tried to find new targets and effective drugs for imatinib-resistant chronic myelogenous leukemia (CML) cells displaying loss of Bcr-Abl kinase target dependence. The imatinib-resistant K562/R1, -R2 and -R3 cells showed profound declines of Bcr-Abl level and concurrently exhibited up-regulation of Bcl-2 and Ku70/80, and down-regulation of Bax, DNA-PKcs and BRCA1, suggesting that loss of Bcr-Abl after exposure to imatinib might be accompanied by other cell survival mechanism. K562/R3 cells were more sensitive to camptothecin (CPT)- and radiation-induced apoptosis than K562 cells, indicating hypersensitivity of imatinib-resistant cells to DNA damaging agents. Moreover, when K562 cells were treated with the combination of imatinib with CPT, the level of Bax and the cleavage of PARP-1 and DNA-PK were significantly increased in comparison with the effects of each drug. Therefore, our study suggests that CPT can be used to treat CML with loss of Bcr-Abl expression.
    Cancer Letters 08/2007; 252(1):75-85. · 5.02 Impact Factor
  • Clinical Lung Cancer 07/2010; 11(4):222. · 2.04 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Molecular pathology involves study of nucleic acids, genes, and gene products.1–9 The development and progression of human cancers are linked to genetic instability and the accumulation of multiple genetic mutations, which can be investigated with the tools of molecular pathology.10–25 Molecular pathology provides a basis for understanding the biology of lung cancer,26–36 including its pathogenetic relationship to tobacco smoking,37–57 and increasingly is providing targets for therapeutic intervention. 58–78 In this section, we briefly review the basic terminology and concepts, as an introduction or refresher to subsequent sections of this chapter, and we discuss nucleic acids, genes, and gene products; replication, translation, and transcription; posttranslational modifications of gene products and protein degradation; transcription factors, cell surface receptors and signaling pathways, the cell cycle, apoptosis, cell survival and DNA damage repair; mutations; and microRNAs and siRNAs.
    05/2010: pages 47-157;

Full-text (2 Sources)

Available from
Sep 25, 2014